Adaptive Biotechnologies ADPT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $276.98M+54.8% | $178.96M+5.1% | $170.28M-8.1% | $185.31M+20.1% | ||
| $71.36M-1.0% | $72.08M-4.6% | $75.55M+30.5% | $57.91M+17.5% | ||
| $205.62M+92.4% | $106.88M+12.8% | $94.72M-25.6% | $127.4M+21.3% | ||
| 74.2%+14.5pp | 59.7%+4.1pp | 55.6%-13.1pp | 68.7%+0.7pp | ||
| $93.77M-8.9% | $102.95M-15.7% | $122.12M-13.9% | $141.76M-0.4% | ||
| $94.57M+11.6% | $84.76M-4.3% | $88.58M-7.3% | $95.6M+0.1% | ||
| $72.7M-0.1% | $72.81M-13.3% | $83.93M-5.2% | $88.53M+18.8% | ||
| $334.1M-2.2% | $341.51M-14.0% | $397.31M+3.1% | $385.49M+6.1% | ||
| -$57.12M+64.9% | -$162.55M+28.4% | -$227.04M-13.4% | -$200.19M+4.2% | ||
| -20.6%+70.2pp | -90.8%+42.5pp | -133.3%-25.3pp | -108%+27.4pp | ||
| -$59.5M+62.7% | -$159.49M+29.2% | -$225.25M-12.5% | -$200.19M+3.4% | ||
| -21.5%+67.6pp | -89.1%+43.2pp | -132.3%-24.3pp | -108%+26.3pp | ||
| -$0.40+63.0% | -$1.08+30.8% | -$1.56-10.6% | -$1.41+4.7% | ||
| -$39.29M+72.6% | -$143.29M+30.0% | -$204.8M-14.2% | -$179.27M+8.1% | ||
| -14.2%+65.9pp | -80.1%+40.2pp | -120.3%-23.5pp | -96.7%+29.6pp | ||
| -$57.12M+64.9% | -$162.55M+28.4% | -$227.04M-13.4% | -$200.19M+4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Adaptive Biotechnologies's revenue?
- Adaptive Biotechnologies (ADPT) generated $295.4M in revenue over the trailing twelve months, up 55.9% year over year.
- Is Adaptive Biotechnologies profitable?
- Adaptive Biotechnologies is not currently profitable: it reported a net loss of $49.7M over the trailing twelve months, a -16.8% net margin.
- What are Adaptive Biotechnologies's profit margins?
- Gross margin is 75.3% and operating margin is -15.8%, with a -16.8% net margin.
- What is Adaptive Biotechnologies's earnings per share?
- Adaptive Biotechnologies's diluted EPS over the trailing twelve months is $-0.33.
- Where does Adaptive Biotechnologies's income statement data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
